Thelansis

Background: In the current scenario, the competitive landscape of oncology TA, where innovation moves rapidly, pharma companies face intense pressure to optimize their pipeline investments. With hundreds of potential cancers and limited resources, selecting the most promising therapeutic indications for early-stage assets is both critical and complex. Traditional prioritization methods usually rely on manual literature reviews, expert panels, and historical analogs, lagging to keep pace with the dynamic nature of clinical, regulatory, and market data, which in turn delays portfolio actions. With a goal to address this challenge, one of our key clients sought a solution from us that would provide a systematic, multi-dimensional, and data-centric approach to prioritize oncology indications for their early-stage pipeline assets. Objective: The primary objective was to enable evidence-based indication prioritization by integrating epidemiological, clinical, and commercial datasets ...